MultiCell Technologies Inc (MCET)

[TPX]

Next good news about ADC immunotherapy!

Oxis International Comments On New York Times Article About Cancer Immunotherapy

LOS ANGELES, CA / ACCESSWIRE / August 1, 2016 / Oxis International Inc. (OTCQB: OXIS and Euronext Paris OXI.PA), a company that has made significant strides in harnessing the immune system to fight cancer, today commented on a New York Times article that examined cancer immunotherapy.

Anthony J. Cataldo, Chief Executive Officer of Oxis, said that, "while the article brought national attention to advances in the fight against cancer, it failed to address the latest scientific progress in the effort to empower the body's own immune system to target and destroy cancer cells."

In July, Oxis announced that its wholly owned subsidiary, Oxis Biotech Inc., has agreed to a major partnership with the University of Minnesota to develop and commercialize cancer therapies using TriKe technology developed by researchers at the university.

TriKE technology has several benefits compared to CAR-T therapy, which is very expensive and has been shown to carry significant side effects. Both Kite Pharma (NASDAQ: KITE) and Juno Therapeutics Inc. (NASDAQ: JUNO) have gained significant attention for their CAR-T efforts.

The Times' article, which carried the headline, "Harnessing the Immune System to Fight Cancer," examined the changing landscape in the way doctors treat cancer.

"They talk very highly about immunotherapy; but this is all very dated information," Cataldo said. "Oxis's Targeted Immunotherapy OXS-1550, OXS-1650 and OXS-3550 are so much further ahead and the target modality makes it truly disruptive and much more specific."

"The difference is non targeted therapies hope to kill specific cancers getting to a general area; but also killing healthy cells indiscriminately. Off the shelf targeted therapies on which Oxis is focused on involves leveraging the immune system to target and destroy specific cancer cells while leaving healthy cells alone. These are far more accurate, less invasive on the patient, less costly and much more effective."

Researchers at the University of Minnesota are currently treating patients in an FDA Phase 1/Phase 2 trial of OXS-1550. Oxis recently announced that six new patients had been added to the trial, bringing to 32 the number of patients participating.

All the new patients are given an approved increased dosage of OXS-1550. It was the increased dosage that was credited with the complete remission of patient Cynthia Cattell.

Ms. Cattell said all other treatments for her aggressive B-cell lymphoma had failed – until she was treated with OXS-1550.

She was the first patient to receive four infusions of the drug over an eight-day span in the Phase 1 clinical trial. One month later, a doctor overseeing the clinical trial found a 75 percent reduction in the size of Cattell's tumor. She has now been cancer-free for almost two years.

The medical journal Science Translational Medicine recently highlighted TriKe research by the University of Minnesota's cancer center.

Science Translational Medicine designated the research as an "Editors' Choice," and said, "TriKEs were superior in restoring potent antigen-specific NK cell responses against AML targets and mediated robust and specific NK cell proliferation."

http://www.otcmarkets.com/news/otc-market-headline?id=571376